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ABSTRACT
Background: Idiopathic pulmonary fibrosis (IPF) is a fatal
interstitial lung disease characterised by accumulation of
activated (myo)fibroblasts and excessive extracellular
matrix deposition. The enhanced accumulation of (myo)-
fibroblasts may be attributed, in part, to the process of
transforming growth factor b1 (TGFb1)-induced epithe-
lial–mesenchymal transition (EMT), the phenotypic
switching of epithelial to fibroblast-like cells. Although
alveolar epithelial type II (ATII) cells have been shown to
undergo EMT, the precise mediators and mechanisms
remain to be resolved. The objective of this study is to
investigate the role of SNAI transcription factors in the
process of EMT and in IPF.
Methods: Using quantitative reverse transcription-PCR
(RT-PCR), immunofluorescence, immunohistochemistry,
western blotting, as well as gain- and loss-of-function
studies and functional assays, the role of SNAI1 and
SNAI2 in TGFb1-induced EMT in ATII cells in vitro was
assessed; and the expression of SNAI transcription
factors was analysed in experimental and human IPF in
vivo.
Results: TGFb1 treatment increased the expression and
nuclear accumulation of SNAI1 and SNAI2, in concert
with induction of EMT in ATII cells. SNAI overexpression
was sufficient to induce EMT, and small interfering RNA
(siRNA)-mediated SNAI depletion attenuated TGFb1-
induced ATII cell migration and EMT. SNAI expression
was elevated in experimental and human IPF and localised
to hyperplastic ATII cells in vivo.
Conclusions: The results demonstrate that TGFb1-
induced EMT in ATII cells is essentially controlled by the
expression and nuclear translocation of SNAI transcription
factors. Increased SNAI1 and SNAI2 expression in
experimental and human IPF in vivo suggests that SNAI-
mediated EMT may contribute to the fibroblast pool in
idiopathic pulmonary fibrosis.
Idiopathic pulmonary fibrosis (IPF) is a progressive
and lethal disorder of major concern due to its
unresolved pathogenesis and limited responsive-
ness to currently available therapies.1 The hallmark
lesions of IPF are fibroblast foci, which are sites
featuring a-smooth muscle actin (aSMA)-positive,
activated (myo)fibroblasts.2 3 Currently, three
major theories attempt to explain the accumula-
tion of activated (myo)fibroblasts in the lungs of
patients with IPF. First, local fibroproliferation of
resident pulmonary fibroblasts in response to
fibrogenic cytokines and growth factors increases
the fibroblast pool.4 Secondly, bone marrow-
derived circulating fibrocytes trafficking to the
lung may serve as progenitors for interstitial
fibroblasts.5–9 Thirdly, alveolar epithelial type II
(ATII) cells, via the process of epithelial–mesench-
ymal transition (EMT), can undergo a phenotypic,
reversible switching to fibroblast-like cells.10–12
The orchestrated series of events during EMT
includes remodelling of epithelial cell–cell and cell–
matrix adhesion contacts, reorganisation of the
actin cytoskeleton, induction of mesenchymal gene
expression and the acquisition of motile capacity.13
During development and disease pathogenesis,
EMT is under tight transcriptional control main-
tained by factors such as Twist, NF-kB, Rho, Rac,
Snai or GSK-3b.13 14 The transcription factors
eliciting EMT in IPF are yet to be identified. In
this context, the zinc finger transcription factor
SNAI1 (also called Snail) and SNAI2 (also called
Slug) have been reported to act as regulators of
EMT during development and disease, including
cancer and organ fibrosis.15 16
Transforming growth factor b1 (TGFb1) repre-
sents a main inducer and regulator of EMT in
multiple organ systems, including the lung.10 17
While the ability of TGFb1 to induce EMT has
recently been described in ATII cells in vitro11 18–22
and in vivo in transgenic mice,12 the molecular
mechanisms that control these dynamics and their
precise role in other experimental models of lung
fibrosis and IPF remain to be elucidated.
This study was performed to examine the
hypothesis that TGFb1 induces EMT via SNAI
transcription factors in ATII cells and that SNAI
transcription factors contribute to the develop-
ment of IPF. In detail, we examined the character-
istics of TGFb1-induced EMT, modulated via SNAI
transcription factor in vitro, and evaluated the
expression pattern of SNAI transcription factors in
experimental as well as human IPF in vivo.
MATERIALS AND METHODS
Reagents
The following antibodies were used in this study:
anti-prosurfactant protein (proSP-C) (Chemicon
International, Temecula, California, USA), anti-
aSMA (Sigma, St Louis, Missouri, USA), anti-e-
cadherin (ECAD) (BD Biosciences, San Jose,
California, USA), anti-tight junction protein
(TJP)1, anti-occludin (OCCL) (Zymed
Laboratories, San Francisco, Calkifornia, USA),
anti-SNAI1 and anti-a-tubulin (Santa Cruz
Biotechnology, Santa Cruz, California, USA),
anti-SNAI2 (Cell Signaling Technology, Beverly,
Massachusetts, USA) and anti-SNAI1 (a gift from
Dr Becker, Institute of Pathology, Technical
University of Munich, Germany). Recombinant
human TGFb1 was purchased from R&D Systems
(Minneapolis, Minnesota, USA).
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Cell culture
The human lung epithelial cell line A549 (ATCC CCL-185;
Manassas, Virginia, USA) was maintained in Dulbecco’s
modified Eagle’s medium (DMEM; Invitrogen, Pasching,
Austria), supplemented with 10% fetal bovine serum (FBS;
PAA Laboratories, Carlsbad, California, USA). Primary mouse
ATII cells were isolated from adult male C57BL/6N mice as
previously described.23
Human tissues
Lung tissue biopsies were obtained from 12 patients with IPF
(mean age (SD) 51.3 (11.4) years; six females, six males) and
nine transplant donors (serving as control subjects) (mean age
47.5 (13.9) years; four females, five males).24 The study protocol
was approved by the Ethics Committee of the Justus-Liebig-
University School of Medicine (AZ 31/93). Informed consent
was obtained from each subject for the study protocol.
Animal tissues
All animal studies were performed in accordance with the
guidelines of the Ethic’s Committee of University of Giessen
School of Medicine and approved by the local authorities. Adult
male C57BL/6N mice were treated with bleomycin and were
sacrificed at the indicated time points.
RNA extraction and reverse transcription-PCR (RT-PCR)
Total RNA was extracted using RNeasy columns (Qiagen,
Hilden, Germany) according to the manufacturer’s protocol,
and PCR amplification was performed with human and mouse
primers (Tables S1 and S2, online supplement).
Quantitative RT-PCR (qRT-PCR)
qRT-PCR was performed as previously described.23 All results
were normalised to the relative expression of the constitutively
expressed gene porphobilinogen deaminase. The relative tran-
script abundance of the target gene is expressed in DCt values
(DCt = Ct reference–Ct target). Relative changes in transcript
levels compared with controls are expressed as DDCt values
(DDCt =DCt treated–DCt control). All DDCt values correspond
approximately to the binary logarithm of the fold change. The
human and mouse primer sequences are depicted in Table S3
and S4, online supplement, respectively.
Small interfering RNA (siRNA) transfection
The siRNA oligonucleotides specific for human SNAI1 and
SNAI2 mRNA (table 1) were obtained from Dharmacon Inc.
(Lafayette, Indiana, USA). A549 cells were transiently trans-
fected with 100 nM SNAI or non-specific siRNA using
Lipofectamine2000 reagent (Invitrogen). At 4 h post-transfec-
tion, cells were treated with TGFb1. Cells were lysed after 24 h
and the efficiency of gene knock-down was monitored.
Migration assay
Cell migration was determined using Boyden chamber assay
(ThinCerts Tissue Culture Inserts, 24-well, pore size 3.0 mm
from Kremsmunster, Austria), as described previously.25 A549
cells were transfected with SNAI1, SNAI2 or non-specific siRNA
at a total concentration of 75 nM, detached, and 56104 cells
were seeded into the Boyden chamber insert. Cells were
cultured for 8 h to allow their attachment to the membrane
and migration was induced by adding TGFb1 (2 ng/ml) to the
medium in the lower wells. After 24 h, cells were fixed and
stained using crystal violet solution, and non-migrated cells
were removed by cotton swabbing. The membranes were
carefully separated from the insert wall, and optical densities of
migrated cells were measured with a GS-800 Calibrated
Densitometer and analysed with Quantity One software.
Statistical analysis of data
Values are presented as the mean (SEM). All DCt values
obtained from qRT-PCR were analysed for normal distribution
using the Shapiro–Wilk test, with the assignment of a normal
distribution with p.0.05. All DDCt values were analysed using
the two-tailed, one-sample t test. Normality of data was
confirmed using quantile–quantile plots. Intergroup differences
of DCt values from patients and bleomycin-treated mice were
derived using a one-tailed, two-sample t test. A one-way
analysis of variance (ANOVA) with Tukey HSD post hoc test
was for studies with more that two groups. A level of p,0.05
was considered statistically significant.
Further experimental procedures
The detailed procedures for western blotting, densitometric
analysis, immunohistochemistry, immunofluorescence, laser-
assisted microdissection and transfection of human SNAI1 and
SNAI2, as well as the sequences of all primers used in this study,
are provided in the online supplement.
RESULTS
TGFb1-induced EMT in ATII cells
Initially, a comprehensive analysis of TGFb1-induced EMT in
ATII cells was performed. We assessed the gene and protein
expression as well as the localisation of epithelial and
mesenchymal markers in primary mouse ATII cells
(Supplementary fig E1) and the human ATII cell line A549.
TGFb1 treatment for 24 h induced changes in aSMA, ECAD
and TJP1 expression and/or localisation, indicative of EMT.
While ECAD and TJP1 staining decreased, an appreciable
number of cells expressing aSMA increased from 5.9% (2.8%)
in vehicle-treated, to 28.2% (8.1%) in TGFb1-treated cells
(fig 1A,B). The presence of aSMA and TJP1 double-positive
cells in TGF-b1-treated, but not in vehicle-treated cells, further
corroborated the occurrence of TGFb1-induced EMT in primary
ATII cells (fig 1A, bottom panels).
SNAI transcriptions factor expression in TGFb1-induced EMT in
ATII cells
We subsequently quantified the mRNA expression patterns of
several EMT marker genes in ATII cells, using qRT-PCR. ATII
cells were treated with TGFb1 in a dose- and time-dependent
manner as indicated (fig 2, Supplementary fig E2). Although the
magnitude of EMT marker gene expression in both cell types
investigated differs, most markers were differentially regulated
after 8 h. TGFb1 treatment led to a decreased expression of the
epithelial cell marker ECAD and occludin (OCCL), concomitant
Table 1 Small interfering RNA (siRNA) sequences
Gene name Sense sequence Antisense sequence
SNAI1-si#1 ACUCAGAUGUCAAGAAGUAUU PUACUUCUUGACAUCUGAGUUU
SNAI1-si#2 GCAAAUACUGCAACAAGGAUU PUCCUUGUUGCAGUAUUUGCUU
SNAI1-si#3 GCUCGGACCUUCUCCCGAAUU PUUCGGGAGAAGGUCCGAGCUU
SNAI1-si#4 GCUUGGGCCAAGUGCCCAAUU PUUGGGCACUUGGCCCAAGCUU
SNAI2-si#1 GGACACACAUACAGUGAUUUU PAAUCACUGUAUGUGUGUCCUU
SNAI2-si#2 UAAAUACUGUGACAAGGAAUU PUUCCUUGUCACAGUAUUUAUU
SNAI2-si#3 GAAUGUCUCUCCUGCACAAUU PUUGUGCAGGAGAGACAUUCUU
SNAI2-si#4 GAAUCUGGCUGCUGUGUAGUU PCUACACAGCAGCCAGAUUCUU
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Figure 1 Transforming growth factor b1
(TGFb1)-induced epithelial–mesenchymal
transition (EMT) in alveolar epithelial type
II (ATII) cells. (A) Immunofluorescence
detection of a-smooth muscle actin
(aSMA), e-cadherin (ECAD) and tight
junction protein 1 (TJP1) was performed
after treatment with TGFb1 (2 ng/ml) or
vehicle for 24 h. Co-localisation of aSMA
(red) and TJP1 (green) was assessed by
immunofluorescence in ATII cells treated
with TGFb1 for 24 h. Nuclei are visible by
496-diamidino-2-phenylindole (DAPI)
staining. Original magnification is 640.
(B) The quantification of the percentage of
aSMA-positive cells 24 h after TGFb1
(2 ng/ml) treatment. The original
magnification of a representative figure
showing immunofluorescence detection
of aSMA (green) with TGFb1 (2 ng/ml) or
vehicle for 24 h is 610. Results are
representative of 10 independent
experiments and data are expressed as
mean (SEM); *p,0.05, n = 10.
Figure 2 SNAI transcription factor expression in transforming growth factor b1 (TGFb1)-induced epithelial–mesenchymal transition (EMT) in alveolar
epithelial type II (ATII) cells. Using quantitative reverse transcription-PCR analysis, the expression pattern of the indicated EMT markers was detected in
A549 (A) and primary mouse ATII cells (B), after TGFb1 (2 ng/ml) treatment for 2 and 8 h, as indicated. Data are expressed as the mean (SEM);
*p,0.05, n = 5. (C and D) Immunofluorescence analysis was performed using a primary antibody directed against SNAI1 and SNAI2 in both cells. The
original magnification of the representative image from three independent experiments is 640. ECAD, e-cadherin; OCCL, occludin; aSMA, a-smooth
muscle actin; VIM, vimentin.
Interstitial lung disease
Thorax 2009;64:1053–1061. doi:10.1136/thx.2009.121798 1055
 group.bmj.com on April 25, 2013 - Published by thorax.bmj.comDownloaded from 
with increased expression of the mesenchymal marker vimentin
(VIM) and aSMA, 8 h after treatment of ATII cells. Notably,
VIM was strongly induced in primary ATII cells, but not in
A549 cells (fig 2A,B). Importantly, we observed a significant
upregulation of both SNAI1 and SNAI2, along with the
alterations in EMT marker gene expression (fig 2A,B).
Since the SNAI transcription factors were regulated at the
mRNA level, we next wanted to assess the protein expression
and function in TGFb1-induced EMT in ATII cells.
Immunofluorescence analysis of TGFb1-treated ATII cells
revealed increased nuclear translocation of endogenous SNAI1
and SNAI2 upon TGFb1 treatment in A549 and primary ATII
cells, respectively (fig 2C,D, Supplementary fig E3). In addition,
SNAI1 and SNAI2 protein expression was increased by TGFb1
in a time-dependent manner, as assessed by western blot
analysis. These changes were in concert with the time-
dependent decrease of ECAD and increased aSMA expression
in response to TGFb1 treatment (fig 3A,B).
EMT induction by SNAI transcription factor overexpression in
ATII cells
To investigate further whether SNAI has a functional role in
inducing EMT in the lung, the full-length SNAI1 and SNAI2
cDNA were cloned into mammalian expression vectors and
transiently transfected into A549 cells (transfection efficiency is
depicted in Suppplementray fig E4). We examined the gene and
protein expression pattern of different EMT marker post-SNAI
transfection. SNAI1 overexpression led to a significantly
increased aSMA expression (fig 4A), which was further
confirmed on the protein level (fig 4B, Supplementary fig
E5A). Interestingly, SNAI2 overexpression revealed significant
changes on the gene and protein level of the epithelial cell
targets ECAD and OCCL; however, no significant changes were
observed for aSMA expression (fig 4C,D and Supplementary fig
E5B). Taken together, overexpression of SNAI transcription
factors is able to induce EMT in ATII cells, even in the absence
of TGFb1.
Effect of SNAI transcription factor silencing on TGFb1-induced
EMT in ATII cells
In order to determine the effect of SNAI1 or SNAI2 on the
process of TGFb1-induced EMT in ATII cells, we next
characterised SNAI mRNA knock-down using four different
sequences of siRNA oligonucleotides targeting SNAI1 and
SNAI2, respectively (Supplementary fig E6). Quantitative and
semi-quantitative RT-PCR analysis revealed that three out of
four SNAI1 (Supplementary fig E6A, B) and SNAI2
(Supplementary fig E6C, D) siRNA oligonucleotides were
effective in reducing the respective mRNA level in response to
TGFb1 treatment. The most effective siRNA oligonucleotides
targeting SNAI1 and SNAI2 were then used to examine the
effect of SNAI depletion on TGFb1-induced EMT. Both SNAI1
and SNAI2 depletion effectively attenuated TGF-b1-induced
EMT in ATII cells (fig 5). SNAI1-depleted ATII cells exhibited a
significantly attenuated decrease in OCCL and TJP1, as well as a
reduced increase in aSMA mRNA levels, as assessed by qRT-
PCR and semi-quantitative RT-PCR 24 h after TGFb1 treat-
ment compared with non-specific scrambled siRNA-treated
ATII cells (fig 5A,B). Similarly, SNAI2 depletion in ATII cells
demonstrated an increase in OCCL and TJP1 mRNA level
compared with TGFb1-treated non-specific scrambled siRNA-
depleted ATII cells, whereas no significant changes have been
observed in mesenchymal marker expression (fig 5C,D).
Effect of SNAI transcription factor silencing on TGFb1-induced
migration in ATII cells
One of the key requirements for the complete process of EMT is
the capability of ATII cells to migrate. TGFb1 induces ATII cell
migration in a dose-dependent manner (Supplementary fig E7).
In order to elucidate the impact of SNAI transcription factor on
TGFb1-induced ATII cell migration, we performed an in vitro
migration assay on SNAI1- and SNAI2-depleted cells stimulated
with TGFb1. After 24 h of TGFb1 treatment, cells transfected
with non-specific siRNA exhibited a fourfold induction of cell
migration (fig 6). Both SNAI1- and SNAI2-depleted cells
exhibited significant reduced migration under baseline and
TGFb1-induced conditions (fig 6).
SNAI transcription factor expression in experimental lung
fibrosis
To analyse whether expression of SNAI transcription factors
was regulated during experimental lung fibrosis, we subjected
mice to bleomycin treatment for 7 or 14 days. On the mRNA
level, a significant increase in SNAI1 has been observed in lung
homogenates from bleomycin-treated mice compared with
saline-treated mice, as assessed by qRT-PCR analysis (fig 7A).
Interestingly, significantly elevated levels of both SNAI1 and
SNAI2 were observed in freshly isolated ATII cells from
bleomycin-treated lungs compared with ATII cells from saline-
treated lungs, as early as 7 days after treatment (fig 7B). Using
Figure 3 Protein expression of epithelial–mesenchymal transition
(EMT) markers in transforming growth factor b1 (TGFb1)-treated alveolar
epithelial type II (ATII) cells. Protein expression of e-cadherin (ECAD), a-
smooth muscle actin (aSMA), SNAI1 and SNAI2 was assessed by
western blot analysis. A549 cells were treated with TGFb1 (2 ng/ml) for
several different times as indicated. Western blot analysis (A) was
performed using primary antibody directed against ECAD, aSMA, SNAI1
and SNAI2. Lamin A/C served as a loading control. (B) Western blots
were scanned and intensity is represented as fold change. Data are
representative of three independent experiments and are expressed as
the mean (SEM); *p,0.05, n = 3.
Interstitial lung disease
1056 Thorax 2009;64:1053–1061. doi:10.1136/thx.2009.121798
 group.bmj.com on April 25, 2013 - Published by thorax.bmj.comDownloaded from 
immunohistochemistry, we next determined the localisation of
SNAI1 and SNAI2 in bleomycin-treated lungs. While SNAI1
was predominantly localised to perivascular mesenchymal cells
and alveolar macrophages in saline-treated lungs, it also
demonstrated localisation in the epithelium and, particularly,
in subepithelial areas, after bleomycin treatment (fig 7C).
Although little or no staining for SNAI2 was detectable in
saline-treated lungs, weak SNAI2 staining localised to the lung
interstitium after bleomycin treatment (fig 7C). aSMA served as
a well-characterised marker of the lung interstitium after
bleomycin treatment.
SNAI transcription factor expression in IPF
Finally, we asked whether SNAI expression was also increased
in the lungs of patients with IPF. To this end, we determined
the mRNA expression in lung homogenates obtained from
patients with IPF and transplant donors. The qRT-PCR analysis
revealed increased levels of SNAI2 gene expression in both lung
homogenates and microdissected alveolar septae from patients
with IPF compared with transplant donors (fig 8A,B).
Immunohistochemistry further confirmed the expression and
localisation of SNAI1 and SNAI2 predominantly in hyperplastic
alveolar epithelial cells in IPF, whereas only weak SNAI1 and
SNAI2 expression was detected in lung specimens of transplant
donors (fig 8C). Western blot analysis further corroborated the
elevated protein level of both SNAI1 and SNAI2 in lung
homogenates from patients with IPF compared with transplant
donors (fig 8D).
DISCUSSION
IPF is the most common form of idiopathic interstitial
pneumonias (IIPs), which exhibits a poor prognosis and
unresponsiveness to currently available therapies, reflecting
our limited understanding of the basic mechanisms and
mediators implicated in the pathogenesis of this disease.1 26 27
While the initial injury in IPF is affecting the alveolar
epithelium, the interstitial fibroblast/activated (myo)fibroblast
represents the key effector cell accumulating in fibroblast foci
and responsible for the increased extracellular matrix deposition
that is characteristic for IPF.28–30 The EMT, a process where
alveolar epithelial cells turn into fibroblast-like cells, has
recently been reported to serve as a source for the fibroblast
pool in tissue fibrosis of the liver, kidney and lung.11 12 31 EMT
was initially described in embryonic development.14 The
orchestrated series of events during EMT involves changes in
cell polarity, loss of epithelial cell markers, induction of
mesenchymal gene expression and enhanced cell migration.13
TGFb1, known as a key profibrotic growth factor, has emerged
Figure 4 Epithelial–mesenchymal transition (EMT) induction by SNAI transcription factor overexpression in alveolar epithelial type II (ATII) cells. EMT
marker expression was analysed by quantitative reverse transcription-PCR (A, C) and western blot (B, D). A549 cells overexpressing human SNAI1 (A,
B) or SNAI2 (C, D) protein for 24 and 48 h; analysis was carried out by comparison with the empty vector (EV) control. The a-tubulin served as the
loading control. Data are representative of five independent experiments and are expressed as the mean (SEM); * p,0.05, n = 5. ECAD, e-cadherin;
OCCL, occludin; aSMA, a-smooth muscle actin.
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as a potent inducer of EMT.17 32 In the present study, we report
that SNAI transcription factors are key regulators of TGFb1-
induced EMT in the lung. Elevated expression of SNAI1 and
SNAI2 was observed in ATII cells in response to TGFb1 in vitro.
Depletion of SNAI1 and SNAI2 using siRNA knock-down in
ATII cells inhibited TGFb1-induced alterations in EMT marker
gene expression and ATII cell migration in response to TGFb1.
Interestingly, ectopic overexpression of SNAI transcription factors
promotes EMT even in the absence of TGFb1. Finally, an
increased level of SNAI1 and SNAI2 in experimental and human
IPF in vivo further indicated a significant contribution of SNAI
transcriptions factors to the process of EMT in lung fibrosis.
At the onset of our studies, we performed a detailed analysis
of the occurrence of EMT in ATII cells in response to TGFb1,
determining marker gene and protein expression and localisa-
tion in primary mouse ATII cells and A549 cells. Upon exposure
to TGFb1, ATII cells demonstrated an increased expression of
mesenchymal markers (such as aSMA) with a corresponding
decrease in epithelial markers (ECAD and TJP1), suggestive of
EMT. EMT was further corroborated by the presence of aSMA
and TJP1 double-positive cells in TGFb1-treated, but not in
untreated cells. These results are in accordance with previous
studies, reporting that TGFb1 induces EMT in lung epithelial
cells in vitro.11 19–21 Recently, TGFb1-induced EMT has also been
demonstrated in vivo in a triple transgenic mouse model.12
Several regulatory molecules have been implicated in the
process of EMT.13 17 Here, we demonstrated increased expres-
sion and nuclear translocation of the zinc finger transcription
Figure 5 Effect of SNAI transcription factor silencing on transforming growth factor b1 (TGFb1)-induced epithelial–mesenchymal transition in alveolar
epithelial type II (ATII) cells. (A, C) Using quantitative reverse transcription-PCR (RT-PCR) analysis, the expression patterns of EMT marker genes was
assessed in A549 cells after treatment with small interfering RNA (siRNA) against SNAI1 (A) and SNAI2 (C), with TGFb1 exposures for 24 h and
compared with control non-specific scrambled siRNA treatment with TGFb1 exposures for 24 h. (B, D) Semi-quantitative RT-PCR analysis; the
expression patterns of EMT marker genes was detected in A549 cells after siRNA treatment against SNAI1 (B) and SNAI2 (D), with TGFb1 exposures
for 24 h (lane 4) and compared with controls (1) non-specific scrambled siRNA treatment with (lane 3) or without (lane 1) TGFb1 for 24 h and (2)
siRNA against SNAI without TGFb1 treatment (lane2). HSPA8 (heat shock 70 kDa protein 8) was employed as loading control. Data are representative
of three independent experiments and are expressed as mean (SEM); * p,0.05, n = 3. ECAD, e-cadherin; OCCL, occludin; scr; scrambled siRNA
oligonucleotide; aSMA, a-smooth muscle actin; TJP1, tight junction protein 1; VIM, vimentin.
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factors SNAI1 and SNAI2 along with EMT in ATII cells. Elevated
levels of SNAI1 mRNA have been reported in TGFb1-treated A549
cells,22 which has been further confirmed in this study. In
addition, SNAI1 induction by TGFb1 has been recently demon-
strated in MDCK cells, a canine renal epithelial cell line.33
Furthermore, it has been demonstrated that SNAI1-deficient
mice die at the gastrulation stage,34 because of their inability to
undergo EMT, reinforcing the importance of the SNAI transcrip-
tion factors in the process of embryonic development.
The impact of SNAI-mediated EMT in pathophysiological
conditions such as cancer or tissue fibrosis, however, is less well
substantiated and requires further investigations. Recently, high
SNAI expression has been associated with poor prognosis and
tumour recurrence in patients with lung cancer.35 In addition,
SNAI1 has been reported to induce chemoresistance of cancer
cells.36 In tissue fibrosis, SNAI-mediated EMT has been proposed
to be involved in kidney fibrosis.37 The comprehensive analysis
presented herein strongly suggests that SNAI1 and SNAI2 are
essential mediators involved in the initiation and perpetuation
of TGFb1-mediated EMT in experimental and human IPF, but
Figure 6 Effect of SNAI transcription factor silencing on transforming
growth factor b1 (TGFb1)-induced migration in alveolar epithelial type II
(ATII) cells. The small interfering RNA (siRNA)-treated A549 cells were
treated or not with TGFb1 for 24 h. The relative migration potential was
assessed using Boyden chamber assay. scr; scrambled siRNA
oligonucleotide. Membranes were scanned and the intensity is
represented as bars. Data are representative of three independent
experiments and are expressed as mean (SEM); * p,0.05, n = 3.
Figure 7 SNAI transcription factor expression in experimental lung fibrosis. Mice were exposed to bleomycin, and lungs were harvested after 7 or
14 days, as indicated. (A) RNA was isolated and quantitative reverse transcription-PCR (qRT-PCR) was performed for SNAI genes in 7 or 14 day
bleomycin- or saline-treated lung homogenates. (B) SNAI gene expression was quantified in primary alveolar epithelial type II (ATII) cells freshly isolated
from 7 or 14 day bleomycin-treated lungs, using qRT-PCR. Data are representative of five independent experiments and are expressed as mean (SEM);
* p,0.05, n = 5. (C) Immunohistochemical analysis of a-smooth muscle actin (aSMA), SNAI1 and SNAI2 localisation was performed in paraffin-
embedded tissue from bleomycin- or saline-treated lungs after 14 days.
Interstitial lung disease
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by no means proof of EMT in IPF in vivo. Since we were able to
inhibit EMT in ATII cells with siRNAs targeting SNAI1 and
SNAI2, it will have to be demonstrated whether in vivo
interference with these factors may lead to an attenuation of
fibrosis. We also present evidence that both SNAI1 and SNAI2
induce EMT even in the absence of TGFb1, hence recapitulating
their role as potent inducers of EMT. It has to be pointed out
that SNAI1 and SNAI2 may differ in their respective target
genes. Our results suggest that SNAI1 preferably regulated
aSMA, whereas SNAI2 alters epithelial targets. This is of special
interest, as cell-specific SNAI expression in vivo may lead to
distinct cell fates. Given that SNAI2 was the dominant
transcription factor regulated in human IPF tissue, we propose
that some ATII cells undergoing EMT in IPF may exhibit an
aSMA-negative fibroblast phenotype mediated by SNAI2.
In IPF, recent studies were able to demonstrate evidence of
EMT in lung tissue biopsies, suggesting that this process
contributes to the increased pool of (myo)fibroblasts in lung
fibrosis,11 12 as well as in allografts after lung transplantation.38
In contrast, another recent study failed to supply evidence for
EMT in pulmonary fibrosis.39 This discrepancy may be due to
the transient nature and complexity of the EMT process, and
further highlights the challenge in this research field.
Taken together, we demonstrated that SNAI transcription
factors mediate EMT in ATII cells in vitro and their expression
is increased in experimental and human IPF in vivo. We
speculate that EMT is an early event in IPF and that activation
and nuclear translocation of SNAI transcription factors con-
stitute an important early regulator of EMT in ATII cells.
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Figure 8 SNAI transcription factor expression in idiopathic pulmoray fibrosis (IPF). (A) Gene expression analysis of SNAI1 and SNAI2 genes was
performed by quantitative reverse transcription-PCR (qRT-PCR) analysis of total RNA derived from lung homogenates of 12 patients with IPF and nine
transplant donors. (B) SNAI1 and SNAI2 mRNA levels were quantified using qRT-PCR in laser-assisted microdissected septae from five patients with IPF and
five transplant donors. Data are expressed as the mean (SEM); *p,0.05, n = 5. (C) Immunohistochemical analysis of SNAI1 and SNAI2 localisation was
performed in a paraffin-embedded lung specimen from patients with IPF or transplant donors. (D) Western blot analysis of SNAI1 and SNAI2 was performed
three times in lung homogenates obtained from six patients with IPF and six transplant donors. Lamin A/C served as the loading control.
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